9月25日，温氏股份（300498）通过电话会议形式，接受了中金公司协助组织的调研，Taikang Asset Management (Hong Kong)、Hao Capital等2家机构共6位机构投资者参与。温氏股份副总裁兼董事会秘书 蒋荣金，投资者关系管理室副主任史志茹接待了来访机构。 本次投资者关系活动类别为电话会议，地点在公司总部。 公司生产经营情况介绍 年初以来，温氏股份强抓基础生产管理和重大疫病防控等工作，疫病防控成效显著，畜禽大生产保持稳 定，核心生产指标持续改善，成本控制成效显著。 -猪业：当前公司猪业大生产稳定，生产经营持续向 好。8月份，公司猪苗生产成本降至260元/头左右，肉猪上市率93%左右，料肉比2.51。尽管8月份对应 期间猪苗成本、饲料成本有所提升，8月份肉猪养殖综合成本仍保持在6.1 - 6.2元/斤，成本控制较为理 想。 -禽业：公司肉鸡生产继续保持高水平稳定。8月份肉鸡上市率95%，料肉比2.86，毛鸡出栏完全成 本为5.8元/斤。 Q&A环节要点养猪业务成本改善原因：核心原因在于上半年畜禽大生产整体稳定，疫病防控效果较 好，肉猪上市率提升，无效损失大幅减少。同时，公司持 ...

Group 1: Company Overview - The company is engaged in stable production management and effective epidemic prevention, leading to improved core production indicators and cost control [2] - The company’s stock code is 300498 and bond code is 123107 [1] Group 2: Swine Production - In August, the cost of piglets decreased to approximately 260 RMB per head, with a market pig listing rate of around 93% and a feed-to-meat ratio of 2.51 [2] - The comprehensive cost of pig farming remains stable at 6.1-6.2 RMB per jin [2] - The company’s PSY (Pigs Weaned per Sow per Year) level is around 27 [5] Group 3: Poultry Production - The company’s meat chicken listing rate in August was 95%, with a feed-to-meat ratio of 2.86 [2] - The total cost of broiler chickens in August was 5.8 RMB per jin [3] - Since September, the sales price of meat chickens has risen to 6.6 RMB per jin, indicating a recovery in profitability for the poultry business [8] Group 4: Cost Management and Future Outlook - The improvement in swine farming costs is attributed to stable production, effective epidemic control, and reduced losses [4] - The company anticipates a continued weak fluctuation in raw material prices in the short term [8]

资料显示，广东广弘控股股份有限公司位于广东省广州市东风中路437号越秀城市广场南塔37楼，成立 日期1985年11月5日，上市日期1993年11月18日，公司主营业务涉及肉类食品供应业务、畜禽养殖业务 和教育出版物发行业务。主营业务收入构成为：冻品销售66.89%，种禽销售8.86%，混合食材销售 7.32%，猪苗销售5.40%，肉猪销售3.67%，冷库经营3.35%，物业出租2.49%，其他0.73%，种猪销售 0.66%，肉鸡销售0.60%，加工肉制品销售0.03%。 从广弘控股十大流通股东角度 数据显示，宏利基金旗下1只基金位居广弘控股十大流通股东。宏利消费红利指数A（008928）二季度 增持1.63万股，持有股数295.51万股，占流通股的比例为0.52%。根据测算，今日浮亏损失约35.46万 元。连续5天下跌期间浮亏损失153.67万元。 9月22日，广弘控股跌1.97%，截至发稿，报5.98元/股，成交6145.26万元，换手率1.80%，总市值34.91 亿元。广弘控股股价已经连续5天下跌，区间累计跌幅8%。 截至发稿，李婷婷累计任职时间3年269天，现任基金资产总规模25.16亿元，任职期间 ...

Group 1: Pig Farming Business - The production cost of piglets decreased from 300-310 RMB per head in January 2025 to 260-270 RMB per head by July 2025, attributed to effective disease control and improved production management [2][3] - The company has a breeding capacity of approximately 46 million heads and a fattening capacity of about 41 million heads [4] - The average net profit for large-scale pig farming in July 2025 was reported at 21 RMB per head, while for small-scale farming it was 6 RMB per head [5] Group 2: Chicken Farming Business - The chicken farming business incurred a loss of approximately 1.2 billion RMB in the first half of 2025, with inventory impairment provisions amounting to about 500 million RMB [10] - The company is optimistic about the future market potential for Chinese native chickens and has initiated various promotional activities to enhance market share [11][12] - The company plans to maintain a steady growth in chicken farming while focusing on cost reduction and efficiency improvements [15] Group 3: Financial Management and Investment - The company aims to reduce its short-term debt ratio to around 45% while increasing cash dividends to investors [17] - Since its listing in 2015, the company has implemented cash dividends 14 times, totaling 28.1 billion RMB, with a cash dividend rate close to 60% [17] - Future fixed asset investments are projected to be between 3 to 5 billion RMB annually, primarily for upgrading and maintaining existing facilities [18]

Group 1: Wens Foodstuff Group - The company has significantly improved pig farming costs in the first half of the year due to stable large-scale production, effective disease control, increased market supply of pigs, enhanced breeding investments, and optimized feed formulations [1] - Wens Foodstuff is actively promoting a three-year initiative called "Strong Technology and Quality Improvement," focusing on refined management and cost reduction in piglet and meat pig production [1] - As of June, the company's debt-to-asset ratio decreased to 50.6%, with a target of around 45% [1] Group 2: Baolingbao Biology - In the first half of 2025, the company achieved total revenue of 139.92 million yuan, a year-on-year increase of 18.02%, and a net profit of 9.53 million yuan, up 37.49% [2] - The revenue from the three core products grew by 32.15%, with the gross profit margin rising to 17.94% [2] - The company’s HMO project is nearing completion, with 2'-FL approved by the health commission, and an enzyme preparation for allulose expected to be approved in the second half of the year [2]

Core Viewpoint - The company believes there is significant room for cost reduction in pig farming and will continue to implement measures to enhance efficiency and reduce costs [1] Group 1: Cost Reduction Strategies - The company will accelerate the progress of the "Strong Technology Improvement" three-year action plan to ensure effective project outcomes [1] - Comprehensive promotion of refined management will be undertaken, utilizing industrial thinking to drive cost reduction and efficiency improvements, with effective implementation paths already explored [1] - The company will vigorously advance the "Piglet Cost Reduction" and "Meat Pig Cost Reduction" special actions while simultaneously managing piglet quality to enhance industry competitiveness [1] Group 2: Technological Innovation - The company has established a technology innovation system that aligns with its development and will increase research and development investment [1] - Key focus areas for technological innovation include livestock breeding, disease prevention, nutritional formulation, and digital applications to promote cost reduction and efficiency across the entire process [1]

Investment Rating - The report maintains a "Positive" outlook on the Agriculture, Forestry, Animal Husbandry, and Fishery industry [2] Core Insights - The overall revenue of the industry remains stable, with significant improvement in the profitability of the breeding chain. In 2024, the SW Agriculture, Forestry, Animal Husbandry, and Fishery industry achieved total operating revenue of CNY 12,411.05 billion, a year-on-year decline of 1.67%. The net profit attributable to shareholders was CNY 479.85 billion, marking a turnaround from losses in 2023. In Q1 2025, the industry achieved total operating revenue of CNY 2,907.39 billion, a year-on-year increase of 8.09%, with net profit attributable to shareholders reaching CNY 133.35 billion, a significant increase compared to the same period last year [4][17][22]. Summary by Sections 1. Agriculture, Forestry, Animal Husbandry, and Fishery Industry - The industry shows overall stable revenue with a significant improvement in profitability. The operating revenue for 2024 was CNY 12,411.05 billion, down 1.67% year-on-year, while the net profit was CNY 479.85 billion, indicating a recovery from losses in 2023. In Q1 2025, the revenue increased by 8.09% year-on-year to CNY 2,907.39 billion, with net profit rising significantly [4][17][22]. 2. Swine Industry - The profitability of the swine industry has improved significantly, with major companies like Muyuan Foods, Wens Foodstuff Group, and New Hope Liuhe reporting revenue growth of 24.43%, 16.64%, and -27.27% respectively in 2024. The net profit for these companies increased by 519.42%, 244.46%, and 90.50% respectively. In Q1 2025, the top five swine companies saw substantial net profit growth, with Shen Nong Group leading at 6510.85% [30][45]. 3. Animal Health - The animal health sector faced significant pressure, with many companies experiencing revenue declines in 2024. However, Q1 2025 showed signs of recovery, particularly in the chemical drug segment, driven by a rebound in prices of veterinary raw materials. The top three companies in revenue growth for Q1 2025 were Huisheng Biological, Jinhai Biological, and Ruipu Biological, with increases of 20.42%, 7.58%, and 5.97% respectively [49][50]. 4. Feed Industry - The feed industry experienced a decline in total production in 2024, with a 2.10% drop year-on-year. However, revenue began to recover in Q1 2025, with leading companies like Bangji Technology and Haida Group showing significant growth. The average gross profit per ton for major feed companies also improved, with Haida Group achieving a gross profit margin of 12.66% in Q1 2025 [62][65][68]. 5. Poultry Industry - The poultry sector showed varied performance across different categories. In 2024, the top three companies in revenue growth were Xiaoming Co., Lihua Co., and Xiangjia Co., with increases of 16.83%, 15.44%, and 8.06% respectively. The profitability of the poultry industry improved significantly, with Lihua Co. leading in net profit growth at 447.72% [76][78].

Group 1: Swine Industry - The domestic supply and demand for pigs is expected to improve marginally by Q2 2025, with pig prices supported and entering a phase of gradual upward movement. External factors such as tariff-driven increases in feed raw material prices and higher costs for imported meat are also contributing positively to pig prices. The swine sector is highlighted as a defensive asset amid macroeconomic shocks, reinforcing investment logic. Recommended stocks include Wens Foodstuff Group, Muyuan Foods, and Juxing Agriculture [4][86]. - In 2024, China's pork production is projected to reach 56.75 million tons, accounting for 49% of global production, with consumption at 57.95 million tons, representing 50% of global consumption. This positions China as the world's largest pork producer and consumer [13][15]. - The average price of pork in 2024 is estimated at 16.8 yuan per kilogram, reflecting an increase of 11.8% year-on-year. The swine farming market size is expected to reach 1.5 trillion yuan, up 11.2% year-on-year [17][32]. Group 2: Poultry Industry - The demand for white chicken remains resilient despite uncertainties from U.S.-China tariff policies and avian influenza outbreaks. The consumption of white feather broilers is expected to improve marginally, with recommended stocks including San Nong Development and He Feng Co [5][94]. - In 2024, the total output of meat chickens in China is projected to reach 14.84 billion, with white feather broilers accounting for 60.85% of this figure. The output of white feather broilers is expected to increase by 2.2% year-on-year [99]. Group 3: Animal Health - The market for piglets and poultry chicks is stable, with a solid demand for poultry chicks supported by increasing poultry farming. The market for ruminant and pet vaccines is also expected to remain robust, with recommended stocks including Bio-Group, Kexin Biology, and Pulaike [6]. Group 4: Planting and Seeds - The focus on food security is emphasized, with companies involved in high-yield genetically modified soybeans likely to benefit from the ongoing U.S.-China trade tensions. The third batch of genetically modified corn varieties is expected to be approved for planting, which may increase the area under cultivation [7]. Group 5: Feed Industry - The recovery of the swine sector is expected to boost domestic demand for feed, while overseas markets present new growth opportunities. The demand for pig feed is anticipated to rebound as pig farming profitability improves and pig stocks gradually recover [8]. Group 6: Pet Industry - The upcoming shopping festivals are expected to drive demand for pet food, with domestic brands likely to gain market share due to increased tariffs on imported high-end products. Recommended stocks include Guibao Pet, Zhongchong Co, and Petty Co [6].

Investment Rating - The investment rating for the company is "Add" and maintained [1] Core Views - The company reported a significant decline in revenue and net profit for the year 2024, with total revenue of 1.043 billion yuan, down 16.77% year-on-year, and a net profit of 93 million yuan, down 46.82% year-on-year. However, the first quarter of 2025 showed a recovery with revenue of 279 million yuan, up 18.32% year-on-year, and a net profit of 53 million yuan, up 93.75% year-on-year, driven by growth in poultry vaccines and pharmaceuticals [4][5] - The company is facing pressure in the pig vaccine segment due to increased competition, while the poultry vaccine and pharmaceutical segments are showing growth. The pet vaccine segment is also emerging as a new growth area, with sales exceeding 46 million yuan in 2024 [5] - The company is implementing marketing strategy adjustments and organizational changes to strengthen cost control and core competitiveness, anticipating a recovery in performance as the pig vaccine market stabilizes and new growth opportunities in pet vaccines arise [6] Financial Summary - The company’s financial performance is projected to improve from 2025 to 2027, with expected earnings per share (EPS) of 0.49 yuan, 0.61 yuan, and 0.68 yuan respectively. The revenue is expected to grow from 1.131 billion yuan in 2025 to 1.259 billion yuan in 2027, with net profit projected to increase from 169 million yuan to 237 million yuan over the same period [7][9]

Investment Rating - The investment rating for the company is "Add" and it is maintained [1] Core Views - The company reported a significant decline in revenue and net profit for the year 2024, with total revenue of 1.043 billion yuan, down 16.77% year-on-year, and a net profit of 93 million yuan, down 46.82% year-on-year. However, in Q1 2025, the company showed signs of recovery with a revenue of 279 million yuan, up 18.32% year-on-year, and a net profit of 53 million yuan, up 93.75% year-on-year, driven by growth in poultry vaccines and pharmaceuticals [4][5] - The performance of different vaccine products varies significantly, with poultry vaccines showing continuous growth, while pig vaccines are under pressure due to increased competition in the swine breeding industry. The company’s revenue from poultry vaccines and antibodies increased by 3.31% and 33.80% respectively in 2024 and Q1 2025, while revenue from pig vaccines decreased by 22.58% and 11.64% respectively [5] - The company is expected to recover as it adjusts its marketing strategy and implements organizational changes, with projected EPS for 2025-2027 being 0.49 yuan, 0.61 yuan, and 0.68 yuan respectively, maintaining an "Add" rating [6] Company Overview - The latest closing price of the company's stock is 13.70 yuan, with a total market capitalization of 4.7 billion yuan. The company has a total share capital of 346 million shares, with a debt-to-asset ratio of 15.2% and a P/E ratio of 50.74 [3][4]